Keros Therapeutics Inc $ 67.15 2.86 (4.45%)
Warning! GuruFocus has detected 1 Severe warning sign with KROS. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Keros Therapeutics Inc () from 2020 to Jan 25 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Keros Therapeutics stock (KROS) PE ratio as of Jan 25 2021 is 0. More Details
Keros Therapeutics PE Ratio (TTM) Historical Data
View and export this data going back to 2020. Start your Free Trial
Keros Therapeutics PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:URGN NAS:ACIU NAS:FREQ NAS:NK NAS:APRE NAS:VKTX NAS:BCEL NAS:ANAB NAS:SNDX NAS:VBIV OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Traded in other countries KROS.USA
Address 99 Hayden Avenue, Suite 120, Building E, Lexington, MA, USA, 02421
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.